A new class of antiretroviral drugs came on the scene in 2003 with the approval of the first entry inhibitor, enfuvirtide (T-20, Fuzeon). Considerable research has been directed toward discovery of additional drugs that target the cell-entry stage of HIV replication, and CCR5 inhibitors--agents that block viral entry via a novel mechanism of action--are poised to join the antiretroviral armamen...

Although more than 20 years of antiretroviral therapy use has resulted in the selection of multidrug-resistant (MDR) HIV-1, new drugs in the traditional and newer antiretroviral drug classes provide an increasing range of options for the effective treatment of HIV-1 infection. While the protease inhibitor (PI) darunavir combined with low-dose ritonavir (DRV/r) appears to be the basis for a very...

Darunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wild-type HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadministe...

The incidence and spectrum of primary AIDS-defining illnesses in human immunodeficiency virus-positive patients receiving antiretroviral drugs may have changed since the introduction of newer antiretroviral agents. We performed a retrospective analysis of patients enrolled in the British Columbia Drug Treatment Program who were ever prescribed antiretroviral drugs between 1 January 1994 and 31 ...